Deep vein thrombosis · orthopaedic (mixed)
Cell salvage showed no clear difference in DVT (up to 90 days) compared with no cell salvage (low certainty).
1 finding from 1 review
Infection (up to 90 days) · orthopaedic (mixed)
It is very uncertain whether cell salvage changes infection (up to 90 days) compared with no cell salvage (very low certainty).
1 finding from 1 review
MI (up to 90 days) · orthopaedic (mixed)
It is very uncertain whether cell salvage changes MI (up to 90 days) compared with no cell salvage (very low certainty).
1 finding from 1 review
Stroke · orthopaedic (mixed)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes neurological complications compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes neurological complications compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
It is very uncertain whether antithrombin changes major bleeding compared with no thromboprophylaxis (very low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic DVT · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found